- Home
- GLBS vs BLRX Comparison
GLBS vs BLRX Comparison
Compare GLBS & BLRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GLBS
- BLRX
- Stock Information
- Founded
- GLBS 2006
- BLRX 2003
- Country
- GLBS Greece
- BLRX Israel
- Employees
- GLBS N/A
- BLRX N/A
- Industry
- GLBS Marine Transportation
- BLRX Biotechnology: Pharmaceutical Preparations
- Sector
- GLBS Consumer Discretionary
- BLRX Health Care
- Exchange
- GLBS Nasdaq
- BLRX Nasdaq
- Market Cap
- GLBS 21.2M
- BLRX 17.0M
- IPO Year
- GLBS 2007
- BLRX 2011
- Fundamental
- Price
- GLBS $1.01
- BLRX $3.74
- Analyst Decision
- GLBS Strong Buy
- BLRX Strong Buy
- Analyst Count
- GLBS 1
- BLRX 2
- Target Price
- GLBS $3.00
- BLRX $19.00
- AVG Volume (30 Days)
- GLBS 35.8K
- BLRX 39.3K
- Earning Date
- GLBS 09-11-2025
- BLRX 08-14-2025
- Dividend Yield
- GLBS N/A
- BLRX N/A
- EPS Growth
- GLBS N/A
- BLRX N/A
- EPS
- GLBS N/A
- BLRX N/A
- Revenue
- GLBS $35,776,000.00
- BLRX $17,251,000.00
- Revenue This Year
- GLBS $5.01
- BLRX N/A
- Revenue Next Year
- GLBS $27.86
- BLRX N/A
- P/E Ratio
- GLBS N/A
- BLRX N/A
- Revenue Growth
- GLBS 17.92
- BLRX 1.19
- 52 Week Low
- GLBS $0.99
- BLRX $2.30
- 52 Week High
- GLBS $2.21
- BLRX $30.66
- Technical
- Relative Strength Index (RSI)
- GLBS 41.54
- BLRX 43.17
- Support Level
- GLBS $1.00
- BLRX $3.50
- Resistance Level
- GLBS $1.11
- BLRX $3.95
- Average True Range (ATR)
- GLBS 0.04
- BLRX 0.28
- MACD
- GLBS 0.00
- BLRX 0.01
- Stochastic Oscillator
- GLBS 12.73
- BLRX 47.56
About GLBS Globus Maritime Limited
Globus Maritime Ltd is a dry bulk shipping company that provides marine transportation services internationally. The company owns, operates, and manages a fleet of dry bulk vessels that transport iron ore, coal, grain, steel products, cement, alumina, and other dry bulk cargo. Its operations are managed by its subsidiary which also provides in-house commercial and technical management for its vessels and also offers consulting services for an affiliated ship management company. It generates maximum revenues by charging customers for the use of vessels to transport dry bulk commodities.
About BLRX BioLineRx Ltd.
BioLine Rx Ltd is a commercial-stage biopharmaceutical company focused on oncology. The company's current development and commercialization pipeline consists of two clinical-stage therapeutic candidates motixafortide (BL-8040), a novel peptide for the treatment of stem-cell mobilization and solid tumors, and AGI-134, an immuno-oncology agent in development for solid tumors. In addition, the company has a legacy therapeutic product called BL-5010 for the treatment of skin lesions. The company has generated revenues from milestone payments under previously existing out-licensing agreements.